Overview

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Status:
Withdrawn
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Single compassionate use subject is an 83 year old woman with a history of lymph node positive breast cancer and recently diagnosed pancreatic cancer in May. With an Eastern Cooperative Oncology Group (ECOG) of 2, it is felt that she cannot tolerate more aggressive chemotherapy. The investigators propose to administer FG-3019 on a compassionate pleas basis in combination with gemzar. The patient is currently being treated and is tolerating gemzar.
Phase:
N/A
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Treatments:
Antibodies, Monoclonal